Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intellikine Inc.

This article was originally published in Start Up

Executive Summary

Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.

You may also be interested in...



Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates

Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.

Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates

Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.

Paloma Pharmaceuticals Inc.

Paloma Pharmaceuticals Inc. is initially opting for an ophthalmology indication for its PI3K program. It plans to bring its lead compound, an allosteric inhibitor, into clinical trials for age-related macular degeneration in 2010. If all goes well, Paloma might move the same compound into a Phase I oncology trial later that year.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel